ClinicalTrials.gg
RecruitingNCT07738172PTR-2Updated Sep 9, 2026

Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

A Phase 3 interventional study of Primary Tumor Resection and Osimertinib in Lung Neoplasms, Non-Small Cell Lung Cancer, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Taiwan University Hospital · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Carcinoma, Non-Small-Cell Lung by National Taiwan University Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · National Taiwan University Hospital.

Planned enrollment
3rd of 19
154 · median 82
Started
2026
with 3 others
Phase 3
Only one
of the 32
Registered
32nd of 32
by date

Among the 32 studies in Carcinoma, Non-Small-Cell Lung by National Taiwan University Hospital, this one is the 3rd largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 3, and was the 32nd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 32 studies in Carcinoma, Non-Small-Cell Lung by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Carcinoma, Non-Small-Cell Lung by National Taiwan University Hospital, or all of them as a file.
02

Study summary

Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation. Although osimertinib can provide effective disease control, most patients eventually experience disease progression, and the primary lung tumor may remain an important site of treatment resistance.

This multicenter, randomized, open-label phase III trial will evaluate whether surgical removal of the primary lung tumor, in addition to continued osimertinib treatment, prolongs progression-free survival in patients with EGFR-mutated oligometastatic non-small cell lung cancer.

All participants will initially receive osimertinib 80 mg orally once daily for 12 weeks. Participants who have a partial response or stable disease according to RECIST version 1.1 and remain suitable for surgery will be randomly assigned in a 1:1 ratio to continue osimertinib alone or to undergo primary lung tumor resection followed by resumption of osimertinib. The study will also evaluate overall survival, safety, pathologic response, quality of life, patterns of disease progression, and changes in molecular biomarkers.

Read the detailed description

This is a multicenter, open-label, parallel-group, randomized controlled phase III trial evaluating primary lung tumor resection in patients with EGFR-mutated oligometastatic stage IV non-small cell lung cancer treated with first-line osimertinib.

The study includes two eligibility assessments. During the first assessment, participants must have histologically or cytologically confirmed stage IV non-small cell lung cancer harboring an EGFR exon 19 deletion or exon 21 L858R mutation, a dominant and potentially resectable primary lung tumor, no more than three involved organs, and no more than 10 distant metastatic lesions.

All enrolled participants will receive protocol-defined induction treatment with osimertinib 80 mg orally once daily for 12 weeks. After induction, participants will undergo restaging. Only participants with partial response or stable disease according to RECIST version 1.1 who remain medically and technically suitable for primary lung tumor resection will undergo randomization.

Eligible participants will be randomly assigned in a 1:1 ratio to one of two groups:

  1. Osimertinib alone; or
  2. Primary lung tumor resection followed by continued osimertinib. Randomization will be stratified by EGFR mutation subtype, presence of brain metastases, and number of distant metastatic lesions.

Participants assigned to the surgical group will undergo therapeutic resection of the primary lung tumor after randomization. The surgical approach and extent of resection will be selected by the treating thoracic surgeon according to accepted standards of care. Osimertinib will generally be resumed 1 to 2 weeks after surgery when wound healing is considered adequate. Participants in both groups will continue osimertinib until disease progression, unacceptable toxicity, withdrawal, or another protocol-defined reason for treatment discontinuation.

Tumor assessments will be performed approximately every 12 weeks and evaluated according to RECIST version 1.1. Local treatment of distant metastatic lesions may be provided when clinically indicated according to standard of care and institutional practice for the PTR group, as permitted by the protocol.

The primary objective is to compare progression-free survival between the two treatment groups. Secondary and exploratory objectives include overall survival, treatment-related adverse events, pathologic response of the primary tumor, quality of life, local-regional progression-free survival, distant metastasis progression-free survival, brain metastasis progression-free survival, polymetastatic progression-free survival, systemic therapy-free survival, and exploratory molecular biomarker outcomes.

03

Conditions studied

  • Lung Neoplasms, Non-Small Cell Lung Cancer

Browse trials for

Keywords

  • non-small cell lung cancer (NSCLC)
  • EGFR mutation
  • stage IV non-small-cell lung cancer
  • Osimertinib
  • Primary tumor resection
  • Oligometastatic non-small cell lung cancer
  • Local consolidative therapy
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 154 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

This study consists of 2 screening phases:

Part 1 screening (before osimertinib induction):

Patients must meet the baseline eligibility criteria, including stage IV NSCLC, EGFR sensitizing mutation (exon 19 deletion or L858R), resectable dominant primary lung lesion, and adequate performance status and organ function.

Part 2 screening (after 12 weeks of protocol-defined osimertinib induction and before randomization):

Patients must complete 12 weeks of osimertinib 80 mg once daily and undergo restaging evaluation. Only patients with partial response (PR) or stable disease (SD) by 1.1, and who remain suitable for thoracic surgery, will proceed to randomization.

Disease distribution must satisfy all of the following: no more than 3 involved organs, one dominant pulmonary primary lesion, the maximal diameter of the dominant primary lung lesion greater than any individual distant lesion, and a total number of distant metastatic lesions fewer or equal than 10. Pleural or peritoneal metastasis confined to a single cavity and amenable to treatment may be considered a single metastatic lesion.

Inclusion criteria for screening part 1

  1. or cytologically confirmed NSCLC.
  2. Age ≥18 years.
  3. AJCC 8th edition stage IV NSCLC.
  4. EGFR sensitizing mutation limited to exon 19 deletion or exon 21 L858R.
  5. 0-1. Patients with must be conscious; patients with bone metastases must not have irreversible severe events such as severe pathological fracture.
  6. The primary lung tumor is considered resectable by the investigator and thoracic surgeon, with surgery intended for maximal regional control.
  7. The patient is able to take oral medication and is expected to receive osimertinib induction therapy.
  8. Major organ function and pulmonary reserve are adequate to tolerate the planned surgery.

Inclusion Criteria for Screening Part 2

Subjects may proceed to randomization only if all of the following criteria are met:

  1. The subject has received first-line protocol-defined osimertinib induction according to the study protocol, consisting of osimertinib once daily (QD) for 12 weeks, and has completed the pre-randomization evaluation.
  2. Restaging imaging has been completed after 12 weeks of induction therapy, and the response is assessed as partial response (PR) or stable disease (SD) according to RECIST version 1.1. In addition, the maximal diameter of the target primary lung tumor before surgery must be greater than the sum of the maximal diameters of the metastatic tumors. PET-CT before surgery or before randomization is recommended to evaluate for newly developed extrathoracic metastases, bone metastases, or mediastinal lymph node involvement. If PET-CT is not performed, the preoperative or pre-randomization imaging assessment should include contrast-enhanced CT scans of the chest and abdomen, including the liver and adrenal glands; brain imaging should be completed with contrast-enhanced CT or MRI. Pleural or peritoneal metastasis confined to a single cavity (for example, unilateral pleural disease) and amenable to treatment may be considered a single metastatic lesion.
  3. Disease distribution after induction therapy meeting all of the following criteria:

    1. no more than 3 involved organs;
    2. one dominant pulmonary primary lesion;
    3. the maximal diameter of the dominant pulmonary primary lesion is greater than any single distant metastatic lesion;
    4. total number of distant metastatic lesions fewer or equal to 10.
  4. After 12 weeks of protocol-defined osimertinib induction, the patient must have PR or SD by RECIST 1.1 and remain eligible for randomization.

    If either of the following conditions is present on restaging imaging:

    1. Poor primary tumor response: the sum of the longest diameters (SLD) of the primary lung tumor after treatment falls within the range of less than 30% decrease and less than 20% increase (that is, -30% \< SLD change \< +20%); or
    2. Polymetastatic condition: the total number of distant metastatic lesions is 6 to 10,

    then the treatment response of the other distant target metastatic lesions must additionally meet an SLD reduction of at least 30% in order for the subject to remain eligible for randomization.

  5. Estimated is greater than 3 months, as judged by the investigator.
  6. The subject remains suitable for primary lung tumor resection, as assessed by the investigator and thoracic surgeon, and has no major comorbidity that would increase surgical risk to an unacceptable level.

Exclusion criteria Subjects meeting any of the following criteria will be excluded from this study. If any of these conditions are identified only after completion of the 12-week induction phase, the subject will not proceed to randomization.

  1. Pathology other than non-small cell lung cancer (NSCLC), or failure to meet the EGFR mutation criteria specified in this study.
  2. EGFR mutation other than exon 19 deletion or exon 21 L858R.
  3. Involvement of more than 3 organs by tumor lesions at post-induction restaging, before randomization.
  4. Total number of distant metastatic lesions greater than 10 at post-induction restaging, before randomization.
  5. No clearly dominant primary pulmonary lesion, or the maximal diameter of the dominant primary pulmonary lesion is not greater than any individual distant metastatic lesion at post-induction restaging, before randomization
  6. Diffuse pleural or peritoneal carcinomatosis that cannot be clearly localized and treated with local definitive therapy.
  7. Progressive disease (PD) on imaging evaluation after 12 weeks of protocol-defined osimertinib induction.
  8. Judged by the investigator or thoracic surgeon to be no longer suitable for thoracic surgery after induction therapy.
  9. Any systemic therapy other than the protocol-defined osimertinib induction for the current stage IV NSCLC.
  10. Any prior EGFR-TKI, chemotherapy, immunotherapy, or other systemic anticancer therapy for the current stage IV NSCLC, except for the protocol-defined osimertinib induction.
  11. Pregnant, breastfeeding, or planning pregnancy during the study period.
  12. Any condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study, or highly likely to be unable to comply with the study procedures, restrictions, or requirements.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Active comparator
    Osimertinib Alone

    Participants will receive osimertinib 80 mg orally once daily for 12 weeks before randomization. After randomization, participants assigned to this arm will continue osimertinib 80 mg once daily until disease progression, unacceptable toxicity, withdrawal, or another protocol-defined reason for treatment discontinuation.

    Drug: Osimertinib

  • Experimental
    Osimertinib Plus Primary Tumor Resection

    Participants will receive osimertinib 80 mg orally once daily for 12 weeks before randomization. After randomization, participants assigned to this arm will undergo therapeutic resection of the primary lung tumor. Osimertinib will generally be resumed 1 to 2 weeks after surgery when wound healing is considered adequate and will be continued until disease progression, unacceptable toxicity, withdrawal, or another protocol-defined reason for treatment discontinuation.

    Procedure: Primary Tumor Resection · Drug: Osimertinib

Interventions

  • ProcedurePrimary Tumor Resection

    Participants assigned to the experimental arm will undergo therapeutic resection of the primary lung tumor after randomization. Acceptable procedures include lobectomy, sleeve lobectomy, bilobectomy, segmentectomy, and wedge resection. The surgical approach may include video-assisted thoracic surgery or thoracotomy. Pneumonectomy and sleeve pneumonectomy are not permitted. The procedure is intended to achieve maximal regional disease control and tumor-free resection margins whenever feasible.

  • Osimertinib will be administered orally at a dose of 80 mg once daily as first-line systemic therapy. Treatment will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or fulfillment of other protocol-defined discontinuation criteria. Dose interruption or reduction will be permitted for treatment-related adverse events according to the study protocol.

07

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    Progression-free survival is defined as the time from randomization to the first documented occurrence of disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Participants without an event will be censored at the date of their last adequate disease assessment.

    Time frame: From randomization to disease progression or death, assessed up to 24 months after randomization.

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from randomization to death from any cause. Participants who are alive at the end of follow-up will be censored at the date they were last known to be alive.

    Time frame: From randomization to death from any cause, assessed up to 48 months after randomization.

  2. Number of Participants With Treatment-Related Adverse Events

    Treatment-related adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number and proportion of participants experiencing treatment-related adverse events will be summarized by treatment group.

    Time frame: From the first dose of osimertinib through 28 days after the last dose

  3. Pathologic Response of the Primary Lung Tumor

    Percentage of residual viable tumor cells in the resected primary lung tumor. Major pathologic response is defined as ≤10% residual viable tumor, and pathologic complete response as no residual viable tumor. This outcome will be assessed only in the surgical arm.

    Time frame: At primary lung tumor resection, generally within 12 weeks after randomization

  4. Change From Baseline in Quality-of-Life Score

    Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, version 3.0 (EORTC QLQ-C30 v3.0), together with the lung cancer-specific module (EORTC QLQ-LC13). Scores for each scale and single-item measure are linearly transformed to a 0-100 scale. Higher scores on the QLQ-C30 Global Health Status/Quality of Life and functional scales indicate better quality of life or functioning, whereas higher scores on the QLQ-C30 symptom scales and QLQ-LC13 symptom scales or items indicate greater symptom burden. No combined total score will be calculated.

    Time frame: Before osimertinib induction, at week 12 before randomization, and at 12 and 24 months after randomization.

Other outcomes

  1. Local-Regional Progression-Free Survival

    Time from randomization to the first occurrence of progression in the primary lung tumor, ipsilateral thorax, regional lymph nodes, or pleura, or death from any cause, whichever occurs first. Participants without an event will be censored at their last adequate disease assessment.

    Time frame: From randomization until locoregional progression or death, assessed up to 5 years

  2. Distant Metastasis Progression-Free Survival

    Time from randomization to the first occurrence of distant progression, a new distant metastatic lesion, or death from any cause, whichever occurs first. Participants without an event will be censored at their last adequate disease assessment.

    Time frame: Time Frame: From randomization until distant progression or death, assessed up to 5 years

  3. Brain Metastasis Progression-Free Survival

    Time from randomization to the first occurrence of intracranial progression, a new brain metastasis, or death from any cause, whichever occurs first. Participants without an event will be censored at their last adequate disease assessment.

    Time frame: From randomization until intracranial progression or death, assessed up to 5 years

  4. Polymetastatic Progression-Free Survival

    Time from randomization to the first radiographic documentation of more than 10 distant metastatic lesions or death from any cause, whichever occurs first. Participants without an event will be censored at their last adequate disease assessment.

    Time frame: From randomization until polymetastatic progression or death, assessed up to 5 years

  5. Start-or-Switch of Systemic Therapy-Free Survival

    Time from randomization to initiation of a new systemic anticancer therapy, switching from the protocol-specified regimen to another systemic regimen, adding a new systemic anticancer agent because of disease progression, or death from any cause, whichever occurs first. Dose interruption, dose reduction, dose re-escalation, or postoperative resumption of protocol-specified osimertinib will not be considered events.

    Time frame: From randomization until systemic therapy initiation, treatment switch, or death, assessed up to 5 years

  6. Plasma EGFR-Mutant Circulating Tumor DNA Variant Allele Frequency

    Plasma circulating tumor DNA will be measured using next-generation sequencing. The variant allele frequency of the tumor-specific EGFR mutation will be expressed as a percentage. Change from baseline will be calculated as the variant allele frequency at each postbaseline assessment minus the baseline variant allele frequency and reported in percentage points.

    Time frame: Baseline before the first dose of osimertinib, Week 12, and Months 6, 12, 18, and 24

  7. Serum Carcinoembryonic Antigen Concentration

    Serum carcinoembryonic antigen concentration will be measured using a clinical laboratory immunoassay and expressed in nanograms per milliliter (ng/mL).

    Time frame: Baseline before the first dose of osimertinib, Week 12, and Months 6, 12, 18, and 24

08

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital
    Taipei, Taipei City 100, Taiwan
    Recruiting
    • Dobbie Pei-Hsing Chen, MD · Contactchenph@ntu.edu.tw · +886-2-2322-0322
    • Chong-Jen Yu, MD · Principal investigator
    • Jin-Shing Chen, MD,PhD · Sub investigator
    • Dobbie Pei-Hsing Chen, MD · Sub investigator
09

References and documents

Individual participant data

Plan to share: Undecided — The individual participant data sharing plan has not yet been finalized. Any future sharing of de-identified participant-level data will be subject to applicable ethical approvals, institutional policies, data-use agreements, and protection of participant confidentiality.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2031, 58 months later.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's planned 58 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 31, 2026
StartEst.
Sep 8, 2026
Primary completionEst.
Aug 1, 2031
CompletionEst.
Aug 1, 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07738172
Responsible party
Statistical Center, NTUHCTC (National Taiwan University Hospital, National Taiwan University Hospital) — Principal investigator
First posted
Jul 31, 2026
Start date
Sep 8, 2026 (estimated)
Primary completion
Aug 1, 2031 (estimated)
Completion
Aug 1, 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Chong-Jen Yu, MD
Contact
jefferycjyu@ntu.edu.tw
+886-2-2322-0322
Chong-Jen Yu, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion